to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
New healthcare businesses in some medical cities may benefit from the Occupy Wall Street movement. Read more about how cities in areas without state incentives for investment could be better off in the near future.
Investments in digital health are on the rise this year, both in terms of the amount of dollars invested and the number of companies getting investment deals. Read more about this trend.
Entrepreneurs raising money for a life sciences startup can take many paths. One CEO makes the case for raising money slowly.
Non-dilutive funding offers startups a lot of advantages, but some entrepreneurs get caught up chasing too many grants. Read more about choosing which funding sources to pursue.
Get in engaged in the conversation with this weeks eMed's 6 to follow in entrepreneurship.
[View the story "eMed's 6 to follow in entrepreneurship" on Storify]Checkout this weeks eMed's 6 entrepreneurs to follow in entrepreneurship.
There are some lessons that no amount of reading can teach an entrepreneur. Sometimes, you just have to learn by doing.
Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in life sciences. For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer,
psoriasis, cardiovascular, metabolic, neurological and renal disorders. Seidenberg has introduced 10 innovative products to market and achieved over 40 regulatory approvals, including new indications and formulations, worldwide. These
products have been successfully commercialized and provided benefits to millions of patients with grievous illnesses, and they have generated several billion dollars of revenue. Prior to joining KPCB, Beth was Senior Vice President, Global
Development, and Chief Medical Officer at Amgen, Inc., the world's largest biotechnology company. During Beth's three years there, her responsibilities included all stages of clinical research, regulatory affairs, safety, health
economics/reimbursement and medical affairs. During her tenure, five innovative products were approved for commercial use. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and
Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. Beth received her BS from Barnard College magna cum laude, Phi Beta Kappa;
and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health. She is a
member of the Johns Hopkins Bloomberg School of Public Health Advisory Board and Barnard College Science Advisory Board.
Women and minorities are offered tactics for honing their approach to angel investors, who are largely white and male, from an entrepreneur who consults in the field.
After coaching others in spin control for years, a cash-strapped entrepreneur had to face the music-and the media-himself. He drew on long-cultivated relationships to tell his story accurately and bring his business out of receivership. Being both proactive and honest, he says, is essential in a crisis situation.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.